Related Experiment Video
Updated: Jul 6, 2026
11:14
Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
Resistance against novel anticancer metal compounds: differences and similarities
Petra Heffeter1, Ute Jungwirth, Michael Jakupec
1Institute of Cancer Research, Department of Medicine I, Medical University Vienna, Austria.
Summary
New metal-based drugs offer alternatives to platinum chemotherapy, but drug resistance remains a challenge. This review explores resistance mechanisms for various metal compounds, questioning if a general metal-drug resistance exists.
Area of Science:
- Oncology
- Medicinal Chemistry
- Pharmacology
Background:
- Platinum-based chemotherapy drugs (cisplatin, carboplatin, oxaliplatin) are mainstays in cancer treatment.
- Their efficacy is hampered by severe side effects and the development of tumor resistance.
- Limited success in clinical development for novel metal-based anticancer agents necessitates further research.
Purpose of the Study:
- To review current knowledge on drug resistance mechanisms against novel metal compounds.
- To investigate potential general resistance phenotypes across different metal-based drugs.
- To guide the development of more effective metal-based anticancer therapies.
Main Methods:
- Comprehensive literature review of existing studies on metal-based anticancer drugs.
- Analysis of reported drug resistance mechanisms for platinum, arsenic, ruthenium, gallium, titanium, copper, and lanthanum compounds.
- Synthesis of findings to identify common resistance patterns.
Main Results:
- Drug resistance is a significant hurdle for both established and novel metal-based anticancer agents.
- Mechanisms of resistance vary but may share common pathways across different metal compounds.
- Few novel metal-based drugs have progressed to clinical approval due to efficacy and resistance issues.
Conclusions:
- Understanding resistance mechanisms is crucial for developing next-generation metal-based cancer therapies.
- A general metal-drug resistance phenotype may exist, warranting further investigation.
- Future research should focus on overcoming resistance to improve clinical outcomes in metal-based cancer chemotherapy.
More Related Videos
05:36Quantifiable and Inexpensive Cell-Free Fluorescent Method to Confirm the Ability of Novel Compounds to Chelate Iron
Published on: February 23, 2024
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:16Drug toxicity: Idiosyncratic Reactions
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...